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Summary 
Methylglyoxal bis-guanylhydrazone (MGBG), a potent inhibitor of polyamine synthesis, has demonstrated 
single agent activity against a number of  tumor types including malignant lymphomas and head and neck, 
esophageal and non-small cell lung cancers. The growth of small cell lung cancer (SCLC) cell lines can be 
arrested by polyamine inhibition. Therefore a phase II trial was conducted in twenty-four patients with 
refractory SCLC. MGBG was administered by intravenous infusion at a dose of 500 mg/m 2 per week for 
four cycles and then every two weeks thereafter. The dose was escalated by 100 mg/m 2 every two weeks in 
the absence of toxicity _> grade 2. One patient achieved a partial response of objectively measurable lung 
disease and supraclavicular adenopathy. Three patients had stable disease. Dose limiting toxicity consisted 
primarily of mild to moderate nausea, vomiting, stomatitis and/or  diarrhea. Myelosuppression was uncom- 
mon and rarely dose limiting. We conclude that MGBG in the dose and schedule used does not have signifi- 
cant activity as a single agent in previously treated small cell lung cancer. 
Introduction 
Methylglyoxal bis-guanylhydrazone (MGBG) is a 
synthetic polycarbonyl compound that has been 
shown to have useful antitumor activity in patients 
with advanced malignant lymphomas and head and 
neck, esophageal and non-small cell lung cancers 
[1]. Although the exact mechanism of its antitumor 
activity is not known, MGBG produces a variety of 
metabolic effects including mitochondrial swelling, 
uncoupling of oxidative phosphorylation and poly- 
amine depletion [2]. Through potent inhibition of 
S-adenosylmethionine decarboxylase (SAM-DC), 
MGBG blocks formation of the amino propyl 
donor required for the synthesis of  spermine and 
spermidine from putrescine in the polyamine path- 
way [3]. Inhibition of  polyamine biosynthesis is of 
interest in that high and unperturbed polyamine 
production appears to be essential to the growth of 
several human tumors including small cell lung 
cancer (SCLC) [4-6].  For these reasons we chose to 
conduct a phase II trial of  MGBG in highly selected 
patients with refractory SCLC. The following re- 
port details the methods and results of  the study. 
Materials and methods 
Twenty-four patients with objectively measurable 
and histologically confirmed SCLC were entered in 
the study. Eligibility requirements included Kar- 
nofsky performance score _ 50, white blood cell 
(WBC) count _> 4000/mm 3, platelet count >_ 
100,000/mm 3 blood urea nitrogen _< 20 mg%, se- 
rum creatinine _< 1.6 mg%, serum bilirubin ___ 
2.0 rag%, no treatment for at least the preceding 
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4 weeks and informed consent. At the start of thera- 
py all patients had a complete medical history, 
physical examination, and laboratory evaluation 
including complete blood cell (CBC) count with 
differential and platelet count, fasting blood glu- 
cose, urinalysis, 12-channel biochemical screening 
profile, carcinoembryonic antigen (CEA) and chest 
roentgenogram. Radionuclide bone and liver scans 
and chest/abdominal CT scans were obtained as 
needed. Each patient had a weekly physical exami- 
nation, toxicity evaluation, CBC, and serum 
chemistries and a monthly evaluation of chest 
roentgenogram or diagnostic scan as needed for 
tumor measurements. 
MGBG was administered by injection through an 
established free-flowing iv line over 30 minutes. 
The initial dose of 500 mg/m '  was administered 
weekly for four cycles and then on alternate weeks. 
Criteria used for dose adjustments followed the 
standard toxicity criteria. The dose was escalated 
by 100 mg/m 2 in the absence of toxicity _> grade 2. 
The dose was attenuated by 25~ in the presence of 
grade 3 toxicity and 50~ in the presence of grade 
4 toxicity. An adequate trial required a minimum of 
three cycles of MGBG. 
Therapeutic response criteria were defined as: 
partial response (PR) - __ 50~ decrease of all 
measurable lesions for at least 4 weeks: Disease 
progression (PD) - a _> 25~ increase in the sum of 
the products of measureable lesions or the appear- 
ance of new lesions; and stable disease (STAB) - 
disease regression less than that needed for PR or 
disease progression less than that needed for PD for 
at least two months. 
Patient characteristics 
There were 15 males and 9 females with a median 
age of 59 years (range, 47-71) and a median Kar- 
nofsky performance status of 70 (range, 50-90). 
All patients had received prior combination che- 
motherapy including cyclophosphamide (100o70), 
doxorubicin (96%), vincristine (96~ VP-16-213 
(46%), cisplatin (46o70), methotrexate (22o70), 
CCNU (22%), or other (25O7o). Sixteen patients 
(67o7o) had received only one prior combination 
chemotherapy treatment regimen. Ten patients 
(42~ had received radiation therapy to whole 
brain and eight patients (33%) had received it to the 
mediastinum. Sixteen patients (67%) had more 
than one site of tumor involvement at entry into this 
study including lung (2), lymph nodes (6), liver (7), 
spleen (1), adrenal (2), bone (2), and subcutaneous 
tissue (1). 
Results 
Twenty-two of 24 patients entered into the study 
are considered evaluable for response and toxicity. 
The two unevaluable cases include one patient who 
had an unrelated death 5 days after the first dose of 
MGBG and another who was lost to follow up after 
2 doses. There was only one objective response 
(PR) in 22 evaluable patients (observed response 
rate = 4.5~ 95~ confidence interval = 0 .2-  
19.8~ The response occurred after 2 doses of 
MGBG in objectively measurable lung disease and 
supraclavicular adenopathy in a patient whose dis- 
ease had progressed after a partial response to CAV 
chemotherapy. The patient died after 6 cycles (2 
months) of MGBG due to progressive brain meta- 
stases but remained in PR extracranially. Three ad- 
ditional patients had stable disease. 
The most common and dose limiting toxicities 
occurred in the gastrointestinal tract. Mild to 
moderate (grade 1-2) diarrhea and/or  stomatitis 
occurred in 10 patients (45%), nausea and vomiting 
occurred in 10 patients (45~ and anorexia oc- 
curred in 7 patients (32~ Grade 1-3 myalgias 
and/or  fatigue occurred in 8 patients (36%). Leu- 
kopenia and thrombocytopenia were uncommon 
and rarely dose limiting. Only two patients deve- 
loped grade 1 leukopenia, and thrombocytopenia 
occurred in 5 patients (3 = grade 1, 1 = grade 2, 
and 1 = grade 4). One patient complained of 
moderate to severe jaw pain for 1-2  days after each 
dose of MGBG and one patient developed grade 1 
dermatitis. 
The median number of doses of MGBG given 
was 4 per patient (range, 1-8). Two patients re- 
quired dose attenuations due to myalgias, throm- 
bocytopenia or gastrointestinal toxicity and three 
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pat ients  to le ra ted  dose escala t ions  (one to 800 
m g / m  2 with only  grade  1 toxici ty) .  
st i tute,  D e p a r t m e n t  o f  Hea l t h  and  H u m a n  Services, 
Bethesda ,  M a r y l a n d .  
Discussion References 
The  resurgence o f  interest  in M G B G  in the late  
1970's was due to the deve lopmen t  o f  a more  to lera-  
ble weekly  schedule  o f  admin i s t r a t i on  [1,7] and  the 
d iscovery  o f  its po tency  as an po lyamine  inh ib i to r  
[3]. The p roduc t s  o f  po lyamine  synthesis ,  put res-  
cine, spe rmid ine  and  spermine  have been impl ica t -  
ed in the  ma in t enance  o f  cell g rowth  and  it was 
hypo thes ized  tha t  the inh ib i t ion  o f  this p a t h w a y  
could  p rov ide  an effect ive tool  for  ar res t ing  the  
g rowth  o f  cancer  cells [4, 51. A l p h a - d i f l u o r o m e t h y l -  
o rn i th ine  ( D F M O ) ,  an i r revers ible  inh ib i to r  o f  or-  
n i th ine  deca rboxy lase  which  cata lyzes  the  ra te  
l imit ing step in po lyamine  synthesis ,  has been o f  
pa r t i cu la r  interest .  L u k  et  al. [6] have shown tha t  
the g rowth  and  v iab i l i ty  o f  h u m a n  S C L C  cells in 
cul ture  is m a r k e d l y  inhib i ted  by  D F M O .  However ,  
only  one pa r t i a l  response  has been observed  in 33 
S C L C  pat ien ts  t rea ted  with D F M O  in phase  I and  
II  tr ials  [8-101.  
In  this s tudy,  M G B G  demons t r a t ed  l i t t le  act ivi ty  
(one PR)  in 24 good  p e r f o r m a n c e  s ta tus  pat ients  
with SCLC,  16 o f  w h o m  had  received on ly  one pri-  
or  t r ea tmen t  regimen.  A l t h o u g h  its pa t t e rn  o f  toxic-  
i ty,  inc luding  lack o f  s ignif icant  mye losuppress ion ,  
make  M G B G  an a t t rac t ive  agent  to i nco rpo ra t e  
in to  c o m b i n a t i o n  regimens  used in S C L C ,  this 
s tudy as well as the negat ive  one r epo r t ed  by  Scher 
et  al. which used a dose and schedule  s imi lar  to ours  
[11] fail  to jus t i fy  fur ther  s tudies o f  this c o m p o u n d .  
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